HYPERTROPHIC CARDIOMYOPATHY (HCM) THERAPEUTICS MARKET ANALYSIS

Regional Analysis

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market - Regional Analysis

On the basis of region, Hypertrophic Cardiomyopathy (HCM) therapeutics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is projected to drive growth of the Hypertrophic Cardiomyopathy (HCM) therapeutics market, owing to increasing prevalence of obesity among the younger population in North America and increasing preference towards a sedentary lifestyle, which are the primary factors augmenting demand for hypertrophic cardiomyopathy therapeutics in these region.

Europe is expected to gain a significant traction over the forecast period, owing to the considerable presence of Hypertrophic Cardiomyopathy (HCM) and increasing number of obese patient in these region. For instance, according to the European Cardiovascular Disease Statistics 2017, the obesity rates are high across the both Europe and EU, including the both adults and children, in 2017. Furthermore, prevalence of diabetes in Europe is high and rapidly increasing. According to the same report, it is found that, EU spends around US$ 251.5 billion in 2017, on cardiovascular disease.